Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial side effects and a high cost. Somatostatin receptor-based therapies have shown promising findings in advanced RrDTC. Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies. This study presents a case of RrDTC who was treated with 177 Lu-PSMA, presumably as a first report in this regard.
INTRODUCTION
Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy so that they need other treatment strategies such as surgery and/or external irradiation to provide a systemic approach to prevent metastatic tumor spread. Tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC but is associated with substantial side effects and a high cost. Somatostatin receptor (SSTR)-based therapies have shown promising findings in advanced RrDTC. [1, 2] Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies. [3] This study presents a case of RrDTC who was treated with 177 Lu-DOTATATE and 177 Lu-PSMA, and is presumably the first report in this regard.
CASE REPORT
The patient was a 42-year-old man who had a progressive disease with neck and lung metastases and was treated with 25.9 GBq (700 mCi)
131
I and also sorafenib for 6 months. The patient had progressive dyspnea due to massive pleural effusions and also repeated surgical intervention in thorax [ Figure 1a ]. The last radioiodine therapy with 7.4 GBq was given after a long period sorafenib treatment, which was associated with the patient experiencing severe side effects. The Ga-PSMA, [3, 4] Our multidisciplinary team proposed PSMA scanning which showed more uptake than octreotide scan in the involved regions [ Figure 1e and f]. He then received 7.4GBq 177 Lu-PSMA, and once more the posttherapy whole-body imaging revealed more uptake than posttherapy whole-body imaging following 177 Lu-DOTATE [ Figure 1g ]. The patient died 2 weeks posttherapy unexpectedly due to cardiac arrest. It should be mentioned that the number of hospitalization after PRRT were fewer than before. Also, an interesting clinical point was that the respiratory function improved in the early days after therapy, so that although he could not walk alone before PRRT, he was able to walk alone for hours in the early days after PRRT.
DISCUSSION
In this study, we present both Lu-DOTATATE. They demonstrated that only one out of five patients depicted a partial response, whereas three patients had a progressive disease. One patient had discordant findings between stable imaging results albeit rising Tg levels. [2] Overall, recent studies demonstrate heterogeneous results ranging from progressive disease under PRRT to favorable results with disease control in up to 60% of patients. [1, 5, 6] To the best of our knowledge, the literature is scarce regarding 177 Lu-PSMA therapy in the patients with RrDTC, so further studies are needed to evaluate this subgroup of DTC.
Such cases illustrate the potential complexity, and interdisciplinary strategies that may end in managing dilemmas. It appears that there is a need for a multidisciplinary pragmatic approach for a change in the management of patients with RrDTC.
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